BEAM Key Statistics, Chart & Performance
The current stock price of BEAM is 31.22 USD. In the past month the price increased by 21.95%. In the past year, price increased by 33.19%.
BEAM Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to BEAM. When comparing the yearly performance of all stocks, BEAM is one of the better performing stocks in the market, outperforming 85.75% of all stocks.
BEAM Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BEAM. While BEAM has a great health rating, there are worries on its profitability.
BEAM Financial Highlights
Over the last trailing twelve months BEAM reported a non-GAAP Earnings per Share(EPS) of -4.43. The EPS decreased by -151.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.63% | ||
| ROE | -42.92% | ||
| Debt/Equity | 0 |
BEAM Forecast & Estimates
23 analysts have analysed BEAM and the average price target is 46.38 USD. This implies a price increase of 48.55% is expected in the next year compared to the current price of 31.22.
For the next year, analysts expect an EPS growth of -0.04% and a revenue growth -27.59% for BEAM
BEAM Ownership
BEAM Latest News, Press Relases and Analysis
BEAM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.68 | 378.84B | ||
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.25B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B |
Related stock screener links
About BEAM
Company Profile
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 483 full-time employees. The company went IPO on 2020-02-06. The firm's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Company Info
BEAM THERAPEUTICS INC
238 Main Street
Cambridge MASSACHUSETTS 02139 US
CEO: John Evans
Employees: 483
Phone: 18573278775
BEAM THERAPEUTICS INC / BEAM FAQ
What does BEAM THERAPEUTICS INC do?
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 483 full-time employees. The company went IPO on 2020-02-06. The firm's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Can you provide the latest stock price for BEAM THERAPEUTICS INC?
The current stock price of BEAM is 31.22 USD. The price decreased by -2.59% in the last trading session.
What is the dividend status of BEAM THERAPEUTICS INC?
BEAM does not pay a dividend.
What is the ChartMill technical and fundamental rating of BEAM stock?
BEAM has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the number of employees for BEAM THERAPEUTICS INC?
BEAM THERAPEUTICS INC (BEAM) currently has 483 employees.
What is the next earnings date for BEAM stock?
BEAM THERAPEUTICS INC (BEAM) will report earnings on 2026-02-23, after the market close.
Can you provide the ownership details for BEAM stock?
You can find the ownership structure of BEAM THERAPEUTICS INC (BEAM) on the Ownership tab.